Intersting overview. I have some remarks/comments/questions.
-when the authors discuss 'harm modeling' they argue that harm is either fixed or variable across subjects. However, it's not unlikely that harm is a combination of both, i.e. absolute bleeding risk with anti-platelet therapy will depend on patient characteristics and additionally some constant disutility may apply for every treated patient.
-what is the additional value of calculating maximum ARIharm(i) or max Relative Value? Seems more logical to establish harm and relative weighing and then calculate whether benefit is large enough to offset this harm.
-in paragraph 1.2 is stated ARRtarget, value adjusted. Rather confusing because harm is assigned a relative value compared to target events (so target event is 1 and harm is for example 0.1, rather than fixing harm at 1) -in the complex model it is assumed that treatment could have more benefits than the effect on target events; would the construction of a composite endpoint incorporating other beneficial events be more easy?
-how is uncertainty incorporated in table 3? Estimating and combining stroke risk & bleeding risk increases the amount of uncertainty of the estimate (apart from the superiority margin) -the evaluation of performance of various calculations is not addressed, does a predicted, value-adjusted, benefit of 1% corresponds to observed empirical benefit? Hence, the question of added clinical usefulness is unanswered.
-the discussion ends with stating that decision curve analysis as proposed by Vickers can be applied to a variable harm scenario. This would require that harm is actually measured similar to the target event, but often measurement of harm receives considerably less attention. Secondly, one would assume that harm can be reliable predicted which can be difficult as incidence is often lower (especially in trials excluding patients at high risk of adverse events)
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GENERAL COMMENTS
This is a well-written and very clear presentation of a framework for translating the results of group-level trials to individual patients. The mathematics is straightforward, and the explanations very helpful.
The major limitations are recognized as well: 1) the current relative rarity of validated clinical prediction guides, particularly for treatment harm, and 2) the even greater rarity of accepted criteria for the ratio of benefit to harm. The author's approach to the second limitation is to present the results for a variety of ratios, which is rational and allows sensitivity analyses across a relevant range of ratios.
VERSION 1 -AUTHOR RESPONSE
Reviewer 1 We thank Prof. Visseren for his comments and criticisms.
Reviewer's comment: when the authors discuss 'harm modeling' they argue that harm is either fixed or variable across subjects. However, it's not unlikely that harm is a combination of both, i.e. absolute bleeding risk with anti-platelet therapy will depend on patient characteristics and additionally some constant disutility may apply for every treated patient.
Re: We agree that a harm can have both a fixed and a variable component. If that occurs, it can be accommodated in our complex model. The fixed and variable components would be entered as separate harms, along with their separate relative values. We changed the wording accordingly (paragraph 1.2, page 10).
Reviewer's comment: what is the additional value of calculating maximum ARIharm(i) or max Relative Value? Seems more logical to establish harm and relative weighing and then calculate whether benefit is large enough to offset this harm.
Reviewer's comment: in the complex model it is assumed that treatment could have more benefits than the effect on target events; would the construction of a composite endpoint incorporating other beneficial events be more easy?
Re: Composite outcomes have been criticized because the constituent components may differ markedly in frequency and/or relative importance to the patient. We argue that it is a strength of our model that effects on and values attached to separate benefits can contribute separately to the treatment recommendation. No change.
Reviewer's comment: how is uncertainty incorporated in table 3? Estimating and combining stroke risk & bleeding risk increases the amount of uncertainty of the estimate (apart from the superiority margin).
Re: The uncertainties in estimates of predicted absolute treatment effects on stroke and bleed were not shown in present Table 3 . We addressed this in revised Table 3 by adding 95% CIs for ARRstroke, ARIbleed, and Required ARRstroke@RV 0.6. We also indicated in the revised table title that this Table provides a framework for particularizing a treatment recommendation; and we added a footnote to the table to caution that the tentative treatment recommendations are based only on point estimates for ARRstroke and ARIbleed, and that the uncertainties denoted by their 95% CIs must be considered before formulating actual treatment recommendations. We revised the text accordingly, see insert on page 14, from line 1. We also added a paragraph in Discussion (Future research objectives a) where we suggest future approaches to the simultaneous resolution of multiple sources of uncertainty in deriving treatment recommendations.
Reviewer's comment: the evaluation of performance of various calculations is not addressed, does a predicted, value-adjusted, benefit of 1% corresponds to observed empirical benefit? Hence, the question of added clinical usefulness is unanswered.
Re: We agree strongly that the clinical usefulness must be tested and that we have not done that here. That is why we advocate empirical validation of the model in RCT datasets using Vickers' method (Discussion [model validation] , and in the Abstract). No change.
Reviewer's comment: the discussion ends with stating that decision curve analysis as proposed by Vickers can be applied to a variable harm scenario. This would require that harm is actually measured similar to the target event, but often measurement of harm receives considerably less attention. Secondly, one would assume that harm can be reliable predicted which can be difficult as incidence is often lower (especially in trials excluding patients at high risk of adverse events).
Re: We agree with the comment that in RCTs the harm is often measured less precisely than the benefit. But we cite an instance in which this was not so (ref 18), and we would argue that imprecision in measurement of harm within RCTs is not a necessary or uniform limitation. We also agree with the comment that the incidence of the harm is often lower, but again that is not uniform. We understand these as comments, and made no change.
Reviewer 2
We thank Prof. Sargent for his comments. As no criticisms were raised, there were no changes in response. 
